ライフサイエンスコーパス: releasing factor

1 mone 44 (DH44), an ortholog of corticotropin-releasing factor.

2 alize with the stress hormone, corticotropin releasing factor.

3 y active clinical candidate of corticotropin-releasing factor 1 (CRF 1) antagonist 1 showed a signifi

4 ally active antagonists of the corticotropin-releasing factor 1 (CRF 1) receptor.

5 de), D2R agonist (quinpirole), corticotropin-releasing factor 1 (CRF1) antagonist (antalarmin), and a

6 ne domains of the glucagon and corticotropin releasing factor 1 (CRF1) receptors to develop improved

7 Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) and Ras-GRF2 are highly si

8 Ablation of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1), a neuronal activator of R

9 n of Ras protein-specific guanine nucleotide releasing factor 1 (RasGrf1), a Ras activator (5-fold, P

10 with Ras protein-specific guanine nucleotide-releasing factor 1 (RASGRF1), leading to impaired activa

11 armacologic inhibition (with a corticotropin-releasing factor 1 receptor antagonist) of pain-related

12 earlier lead pyrazinone-based corticotropin-releasing factor-1 (CRF(1)) receptor antagonist, reveale

13 al-like state characterized by corticotropin-releasing factor-1 (CRF(1)) receptor antagonist-reversib

14 Evidence suggests that corticotropin-releasing factor-1 (CRF(1)) receptor antagonists may off

15 ed as potent and orally active corticotropin-releasing factor-1 (CRF(1)) receptor antagonists.

16 s to palatable food results in corticotropin-releasing factor-1 (CRF1) receptor antagonist-reversible

17 26907 in the ras-specific guanine-nucleotide releasing factor 2 (RASGRF2) gene, encoding a protein th

18 e processes; Ras-specific guanine nucleotide releasing factor 2 (RasGRF2).

19 ene (Ras protein-specific guanine nucleotide-releasing factor 2) with all clinical events except stro

20 After considering the releasing factor (66.6%) from the swab, the final accura

21 Corticotropin-releasing factor, a stress-related neuropeptide implicat

22 id peptide function, increased corticotropin-releasing factor activity).

23 ess neurotransmitters, such as corticotropin-releasing factor and dynorphin, in the neurocircuitry of

24 ing by increased expression of corticotropin-releasing factor and its feedback regulation of TLR4 exp

25 and Hcrt systems in which the corticotropin-releasing factor and N/OFQ systems coordinately modulate

26 sensitizes the LC-NE system to corticotropin releasing factor and stress.

27 (especially neuropeptide Y and corticotropin-releasing factor) are modulated by alcohol drinking duri

28 Corticotropin releasing factor binding protein (CRF-BP) was originally

29 Corticotropin releasing factor-binding protein (CRF-BP) binds CRF and

30 ed Crk SH3 domain-binding guanine-nucleotide releasing factor (C3G) binding to CrkII, whereas inhibit

31 Infusion of hypothalamic-releasing factors can reactivate the thyroid axis in pat

32 othalamus and primarily in non-corticotropin releasing factor-containing neurons of the bed nucleus o

33 os activation were observed in corticotropin releasing factor-containing neurons of the paraventricul

34 at baseline and in response to corticotropin-releasing factor (CRF) (0.5 microg kg(1)) plus arginine

35 BDNF signaling is mediated by corticotrophin-releasing factor (CRF) acting in the NAc.

36 s, including a coordination of corticotropin-releasing factor (CRF) actions at both of its receptors,

37 We report that corticotropin-releasing factor (CRF) acts in the ventral tegmental are

38 also posit a central role for corticotrophin-releasing factor (CRF) and an interaction between CRF an

39 tine SA on the coexpression of corticotropin-releasing factor (CRF) and arginine vasopressin (AVP) mR

40 gh it has long been known that corticotropin-releasing factor (CRF) and CRF receptors are prominent i

41 esent review is on the role of corticotropin-releasing factor (CRF) and CRF-related peptides in the d

42 ng-term alterations in central corticotropin-releasing factor (CRF) and glucocorticoid receptor (GR)

43 ion between the stress hormone corticotropin releasing factor (CRF) and glutamate release onto dopami

44 d to partially colocalize with corticotropin-releasing factor (CRF) and growth hormone-releasing horm

45 xtrahypothalamic expression of corticotropin-releasing factor (CRF) and its G-protein-coupled CRF1 an

46 The stress neuropeptide corticotropin releasing factor (CRF) and its receptors (CRF-R1, CRF-R2

47 Corticotropin-releasing factor (CRF) and nociceptin/orphanin FQ (nocic

48 europharmacological actions of corticotropin-releasing factor (CRF) and norepinephrine in extrahypoth

49 Release of the neuropeptides corticotropin-releasing factor (CRF) and orexin-A in the ventral tegme

50 Corticotropin-releasing factor (CRF) and related peptides play a role

51 The circadian activity of corticotropin releasing factor (CRF) and the hypothalamic-pituitary-ad

52 The corticotropin releasing factor (CRF) antagonist, alpha-helical CRF(9-4

53 e report the identification of corticotropin-releasing factor (CRF) as a critical component of the ca

54 Exogenous corticotropin-releasing factor (CRF) but not corticosterone mimicked t

55 ne arm of the stress response, corticotropin-releasing factor (CRF) can act in the brain to modulate

56 ase of neuromodulators such as corticotropin-releasing factor (CRF) can drive drug-dependent behavior

57 To investigate corticotropin-releasing factor (CRF) contributions to fear memory in L

58 Corticotropin releasing factor (CRF) coordinates the brains responses

59 e stress-related neuropeptide, corticotropin-releasing factor (CRF) directs this by a bimodal regulat

60 the central extrahypothalamic corticotropin-releasing factor (CRF) expression is associated with str

61 of an acute colitis on central corticotropin-releasing factor (CRF) expression.

62 The corticotropin releasing factor (CRF) family of ligands and their recep

63 The corticotrophin-releasing factor (CRF) family of neuropeptides and their

64 enced by the highly conserved corticotrophin-releasing factor (CRF) family of peptides and receptors

65 The corticotropin-releasing factor (CRF) family of peptides includes CRF a

66 tin 3 (Ucn 3), a member of the corticotropin-releasing factor (CRF) family of peptides, is strongly e

67 tin 2 (Ucn2), a peptide of the corticotropin-releasing factor (CRF) family, binds with high affinity

68 n of the stress neuromediator, corticotropin-releasing factor (CRF) has been implicated in these diso

69 levant PI cells identified the corticotropin-releasing factor (CRF) homolog, DH44, as a circadian out

70 e self-administration, reduced corticotropin-releasing factor (CRF) immunodensity in the paraventricu

71 ence of somatostatin (SS) and corticotrophin-releasing factor (CRF) in forebrain neurons that project

72 lation of cytosolic calcium by corticotropin-releasing factor (CRF) in midbrain dopamine neurons.

73 k indicates a crucial role for corticotropin-releasing factor (CRF) in neurobiological responses asso

74 support a modulatory role for corticotropin-releasing factor (CRF) in regulating the dorsal raphe nu

75 ole of the stress neurohormone corticotropin-releasing factor (CRF) in stress-induced binge eating in

76 work hypothesizing a role for corticotropin-releasing factor (CRF) in the IC during craving and rela

77 tionship between dynorphin and corticotropin-releasing factor (CRF) in the induction of dysphoria, th

78 ith the stress-related peptide corticotropin-releasing factor (CRF) in the LC.

79 ibution of the stress hormone, corticotropin-releasing factor (CRF) in the mouse brain.

80 tly described the existence of corticotropin-releasing factor (CRF) in the mouse cochlea.

81 thasone (DEX) inhibition, and corticotrophin-releasing factor (CRF) induced activation.

82 d that the stress neurohormone corticotropin-releasing factor (CRF) inhibits 5-HT neurons in the dors

83 ggests that catecholamines and corticotropin-releasing factor (CRF) interact in a serial manner to ac

84 ces the release of the peptide corticotropin-releasing factor (CRF) into the ventral tegmental area (

85 Corticotropin-releasing factor (CRF) is a key mediator of the behavior

86 Corticotropin-releasing factor (CRF) is also known as a stress-related

87 Corticotropin-releasing factor (CRF) is an important link between stre

88 The neuropeptide corticotropin-releasing factor (CRF) is believed to play a role in a n

89 Corticotropin-releasing factor (CRF) is critical for the endocrine, au

90 emonstrate that, in the vBNST, corticotropin releasing factor (CRF) is expressed in neurons that inne

91 Corticotropin-releasing factor (CRF) is expressed in the Ce, has a rol

92 Corticotrophin-releasing factor (CRF) is expressed in the central nucle

93 Corticotropin releasing factor (CRF) is the primary mediator of stress

94 Corticotropin-releasing factor (CRF) mediates anxiogenic responses by

95 t experiments examined whether corticotropin-releasing factor (CRF) modulates memory consolidation vi

96 Corticotrophin-releasing factor (CRF) modulates the influence of stress

97 5, we measured AT(1) receptors corticotropin-releasing factor (CRF) mRNA and immunoreactive CRF in th

98 Corticotropin-releasing factor (CRF) mRNA expression in the hypothalam

99 eliable increases in Fos-ir or corticotropin-releasing factor (CRF) mRNA in the PVH.

100 duction and relative levels of corticotropin-releasing factor (CRF) mRNA.

101 on, potentially by activating corticotrophin releasing factor (CRF) neurons in the anterolateral cell

102 d activates a subpopulation of corticotropin-releasing factor (CRF) neurons in the bed nucleus of the

103 pecifically recruited GABA and corticotropin-releasing factor (CRF) neurons in the mPFC and produced

104 hip between corticosterone and corticotropin-releasing factor (CRF) on both beta-amyloid (Abeta) and

105 of an intravenous injection of corticotropin-releasing factor (CRF) on fructose malabsorption and the

106 was to examine the ability of corticotropin releasing factor (CRF) or antibody to insulin growth fac

107 ry but did not increase either corticotropin-releasing factor (CRF) or corticosterone.

108 , arginine-vasopressin (AVP), corticotrophin-releasing factor (CRF) or tyrosine hydroxylase (TH).

109 Injection of corticotropin-releasing factor (CRF) or urocortin III, key mediators o

110 Corticotropin-releasing factor (CRF) orchestrates the stress response,

111 The corticotropin-releasing factor (CRF) peptide hormone family members co

112 Corticotropin releasing factor (CRF) plays a major role in CNS respons

113 Because corticotropin-releasing factor (CRF) plays a role in stress responses,

114 derable evidence suggests that corticotropin-releasing factor (CRF) plays an important role in regula

115 The corticotropin-releasing factor (CRF) receptor 1 (CRFR1) is a target fo

116 eta elevation are dependent on corticotropin-releasing factor (CRF) receptor 1 signaling and an intac

117 Corticotropin-releasing factor (CRF) receptor activation within the ba

118 The corticotropin-releasing factor (CRF) receptor CRFR2 is expressed widel

119 awal was mediated by increased corticotropin releasing factor (CRF) receptor-1 expression and signall

120 Corticotropin-releasing factor (CRF) receptors are found in stress-rel

121 Because corticotropin-releasing factor (CRF) receptors are implicated, we comp

122 Natural peptide agonists of corticotrophin-releasing factor (CRF) receptors bind to the receptor by

123 lation increases the levels of corticotropin-releasing factor (CRF) receptors in the serotonergic dor

124 Corticotropin-releasing factor (CRF) receptors-which bind the hormone

125 Corticotropin releasing factor (CRF) regulates physiological and behav

126 e stress-related neuropeptide, corticotropin-releasing factor (CRF) regulates the dorsal raphe nucleu

127 e through alterations in brain corticotropin-releasing factor (CRF) regulation of neurocircuitry invo

128 Corticotropin-releasing factor (CRF) signaling at the CRF1 receptor (C

129 Alterations in corticotropin-releasing factor (CRF) signaling pathways have been impl

130 Over the past few decades, corticotropin-releasing factor (CRF) signaling pathways have been show

131 Activation of corticotropin-releasing factor (CRF) signaling pathways mediates both

132 nforcement is a recruitment of corticotropin-releasing factor (CRF) signaling within the amygdala.

133 dies have implicated the brain corticotropin-releasing factor (CRF) stress systems in mediating the n

134 VN) have been shown to inhibit corticotropin releasing factor (CRF) synthesis via GABA(A) receptors.

135 trahypothalamic stress peptide corticotropin-releasing factor (CRF) system and activation of CRF(1) r

136 H secretion by activating the corticotrophin-releasing factor (CRF) system and sympathoadrenal pathwa

137 Dysregulation of the corticotropin-releasing factor (CRF) system has been implicated in man

138 The corticotropin releasing factor (CRF) system in the central amygdala (C

139 The corticotropin releasing factor (CRF) system in the central amygdala (C

140 The corticotropin-releasing factor (CRF) system is the primary central med

141 ncluding the extrahypothalamic corticotropin-releasing factor (CRF) system, following long-term drug

142 The corticotropin-releasing factor (CRF) system, which is involved in stre

143 gdala (Neo-A) lesions on brain corticotropin-releasing factor (CRF) systems and hypothalamic-pituitar

144 The corticotropin-releasing factor (CRF) type 1 receptor (CRF1R) for the 4

145 Systemic blockade of corticotropin-releasing factor (CRF) type 1 receptors (CRFR1s) reduces

146 gdala (CeA), ethanol acts via corticotrophin-releasing factor (CRF) type 1 receptors to enhance GABA

147 Corticotropin releasing factor (CRF) within the ventral tegmental area

148 Corticotropin-releasing factor (CRF), a 41 amino acid peptide, mediate

149 We investigated how corticotrophin releasing factor (CRF), a critical stress response media

150 Here we report that corticotropin-releasing factor (CRF), a neuropeptide released in respo

151 e number of neurons expressing corticotropin releasing factor (CRF), a neuropeptide that has a promin

152 imolecular interaction between corticotropin-releasing factor (CRF), a neuropeptide, and its type 1 r

153 ited different sensitivity to corticotrophin-releasing factor (CRF), a stress hormone that has been i

154 this, the CEA highly expresses corticotropin-releasing factor (CRF), an important modulator of stress

155 excitatory amino acids (EAAs), corticotropin-releasing factor (CRF), and endogenous opioids acting at

156 opeptide related to vertebrate corticotropin-releasing factor (CRF), and its receptor, Dh44R1.

157 regional, CCK-8, substance P, corticotropin releasing factor (CRF), and neuropeptide Y levels in adu

158 r modulation by dopamine (DA), corticotropin-releasing factor (CRF), and their combination (DA plus C

159 The neuroactive substances corticotropin-releasing factor (CRF), arginine-vasopressin (AVP), hist

160 is thought to communicate via corticotropin-releasing factor (CRF), but studies have yet to examine

161 The neuropeptide, corticotropin-releasing factor (CRF), coordinates the physiological an

162 Corticotropin-releasing factor (CRF), encoded by the CRH gene, is a ke

163 Corticotrophin releasing factor (CRF), enkephalin (ENK), and dynorphin

164 ed receptor B1 family includes corticotropin-releasing factor (CRF), growth hormone-releasing hormone

165 axis-activating neuropeptide, corticotropin-releasing factor (CRF), may be the keystone in drug-indu

166 nd measured mRNA expression of corticotropin releasing factor (CRF), neuropeptide Y (NPY) and proopio

167 es indicate the involvement of corticotropin-releasing factor (CRF), noradrenaline, dopamine, glutama

168 Corticotropin-releasing factor (CRF), originally characterized as the

169 Corticotropin-releasing factor (CRF), the major stress peptide in the

170 e focus is on the receptor for corticotropin-releasing factor (CRF), the orchestrator of the stress r

171 Corticotropin-releasing factor (CRF), the stress-related neuropeptide,

172 oradrenergic substrates [via a corticotropin-releasing factor (CRF)-dependent mechanism] that regulat

173 nd inhibitory transmission in corticotrophin-releasing factor (CRF)-expressing dorsal-medial (mpd) ne

174 en shown previously to cause a corticotropin-releasing factor (CRF)-mediated increase in tonic locus

175 Corticotropin-releasing factor (CRF)-mediated mechanisms in the bed nu

176 tin 1 (Ucn 1) is an endogenous corticotropin releasing factor (CRF)-related peptide.

177 Corticotropin-releasing factor (CRF)-related peptides can modulate str

178 e prototypical stress hormone, corticotropin releasing factor (CRF).

179 e stress-related neuropeptide, corticotropin-releasing factor (CRF).

180 the anxiogenic neuromodulator, corticotropin releasing factor (CRF).

181 he stress-related neurohormone corticotropin-releasing factor (CRF).

182 erminate of these responses is corticotropin-releasing factor (CRF).

183 parabrachial nucleus coexpress corticotropin-releasing factor (CRF).

184 that produce the neuropeptide corticotropin-releasing factor (CRF).

185 uding neuropeptide Y (NPY) and corticotropin-releasing factor (CRF).

186 the stress-sensitive peptide, corticotropin releasing factor (CRF).

187 ocorticoid receptors (GRs) and corticotropin-releasing factor (CRF).

188 opaminergic neurons expressing corticotropin-releasing factor (CRF).

189 The mammalian corticotropin releasing factor (CRF)/urocortin (Ucn) peptide hormones

190 nal aggression) is impaired by corticotropin-releasing factor-(CRF) related peptides, but where these

191 density, stress neuropeptide (corticotropin releasing factor--CRF) levels, and plasma corticosterone

192 tested the hypothesis that the corticotropin-releasing factor (CRF1) antagonist GSK561679 differentia

193 ticoliberin family include the corticotropin releasing factors (CRFs), sauvagine, the urotensins, and

194 transcriptionally activated in corticotropin releasing factor-expressing cells.

195 region-specific alterations of corticotropin-releasing factor expression and promoter methylation, ch

196 neuropeptides vasopressin and corticotropin-releasing factor facilitate, while serotonin inhibits, a

197 rs, which bind peptides of the corticotropin releasing factor family and are key mediators in the str

198 NGF and the hormone urotensin (corticotropin-releasing factor family ligand).

199 ently identified member of the corticotropin-releasing factor family, is expressed in discrete neuroe

200 RasGRP1, a guanine nucleotide-releasing factor for Ras, plays an important role in pos

201 Human recombinant histamine-releasing factor has also recently been shown to induce

202 n of cholecystokinin and secretin release by releasing factors have also been elucidated.

203 al. provide a causal link between histamine-releasing factor (HRF) interactions with IgE and food al

204 lacks a secreted factor related to histamine-releasing factor (HRF).

205 Histamine-releasing factor (HRF; also known as translationally con

206 ther suggest that an activated corticotropin-releasing factor/hypothalamic-pituitary-adrenal axis sys

207 thropin-releasing hormone, and corticotropin-releasing factor immunoreactive cells in the paraventric

208 s the physiological actions of corticotropin-releasing factor in the anterior pituitary gland and the

209 l axis, including signaling by corticotropin-releasing factor, in the pathophysiology of PTSD.

210 A1 and aromatase enhanced local bone marrow-releasing factors, including androgen receptor, estrogen

211 Corticotropin-releasing factor infusions into LA impair the consolidat

212 Corticotropin-releasing factor infusions into the central nucleus of t

213 While corticotrophin releasing factor is the prototypic member of this class,

214 cleave both factor IX peptide bonds prior to releasing factor IX abeta.

215 rebrospinal fluid cortisol and corticotropin-releasing factor levels.

216 s in restraint-induced Fos and corticotropin-releasing factor mRNA expression in the neurosecretory r

217 cting to vasopressinergic and corticotrophin releasing factor neurons in the paraventricular nucleus,

218 acts with the neuromodulators, corticotropin-releasing factor, norepinephrine, dopamine, and serotoni

219 role of brain stress systems (corticotropin-releasing factor, norepinephrine, orexin [hypocretin], v

220 l impact of treatment with such hypothalamic releasing factors on recovery from critical illness as w

221 lockade of the stress hormone corticotrophin-releasing factor or of peripheral GC action, as well as

222 ior hypothalamus that may gate corticotropin-releasing factor output from the amygdala to the anterio

223 n of the brain stress system's corticotropin-releasing factor outside of the hypothalamus in the exte

224 Cohesin dynamics are controlled by the releasing factors Pds5 and Wapl and the cohesin stabiliz

225 this region of receptors for corticotrophin-releasing factor, pituitary adenylate cyclase-activating

226 appetite regulation, including corticotropin releasing factor, pro-opiomelanocortin B, and glucose tr

227 elopmental stage Ras-GRF (guanine nucleotide-releasing factor) proteins are not involved.

228 logical consequence of central corticotropin-releasing factor receptor (CRF-R) activation.

229 ed differential involvement of corticotropin-releasing factor receptor (CRFR) 1 and 2 in acute stress

230 f signaling through the type 1 corticotropin-releasing factor receptor (CRFR1).

231 dministration of the selective corticotropin-releasing factor receptor 1 (CRF(1)) antagonist R121919

232 n, we examined the role of the corticotropin-releasing factor receptor 1 (CRF(1)) in this behavior as

233 haracterize the effects of the corticotropin-releasing factor receptor 1 (CRF-R1) antagonist, GW87600

234 (NE) receptors (alpha1) via a corticotropin-releasing factor receptor 1 (CRF-R1)-dependent mechanism

235 g the efficacy of GSK561679, a corticotropin-releasing factor receptor 1 (CRF1 receptor) antagonist i

236 We describe a novel corticotropin-releasing factor receptor 1 (CRF1) antagonist with advan

237 Blockade of corticotropin-releasing factor receptor 1 (CRF1) suppresses stress-ind

238 member of a class B GPCR, the corticotropin releasing factor receptor 1 (CRF1R).

239 Corticotropin-releasing factor receptor 1 (CRFR1) mediates the physiol

240 what has been observed for the corticotropin-releasing factor receptor 1 (CRFR1), SAP97 expression is

241 r-activated receptor gamma and corticotropin-releasing factor receptor 1 were notable exceptions.

242 ivated by either neurokinin I, corticotropin-releasing factor receptor 1, or dopamine D(1) receptors.

243 Mice deficient in corticotropin-releasing factor receptor 2 (CRF2) (C57BL/6J:129Sv backg

244 ed significant upregulation of corticotropin releasing factor receptor 2 (CrfR2) in the amygdala of m

245 constitutive activation of the corticotropin-releasing factor receptor family homologue SEB-3.

246 ent study examines the role of corticotropin releasing factor receptor subtypes 1 and 2 (CRFR1, CRFR2

247 CRF(2(a))R and the homologous corticotropin-releasing factor receptor type 1 (CRF(1)R) possessing a

248 vestigated whether blockade of corticotropin-releasing factor receptor type 1 (CRF-R1) could prevent

249 ctions in anandamide driven by corticotropin-releasing factor receptor type 1 (CRF1) potentiation of

250 re the interaction between the corticotropin releasing factor receptor type 1 (CRF1R) and its native

251 ed interactions of the class B corticotropin-releasing factor receptor type 1 (CRF1R) with two peptid

252 Corticotropin-releasing factor receptor type 1 (CRFR1) is involved in

253 compartments, we show that the corticotropin-releasing factor receptor type 1 has a specific monomer/

254 nsmembrane domain of the human corticotropin-releasing factor receptor type 1 in complex with the sma

255 The corticotropin-releasing factor receptor type 1 is a class B receptor w

256 librium is established for the corticotropin-releasing factor receptor type 1.

257 Corticotropin-releasing factor receptor type 2 (CRFR2) has been implic

258 central stress response, while corticotropin-releasing factor receptor type 2 (CRFR2) has been sugges

259 bserved abnormal expression of corticotropin-releasing factor receptor type 2 (CRFR2) to be associate

260 The corticotropin-releasing factor receptor type 2a (CRF(2(a))R) possesses

261 Corticotropin-releasing factor receptor-1 (CRF(1)) mediates the stress

262 pyrazolo[1,5-a]-1,3,5-triazine corticotropin releasing factor receptor-1 (CRF(1)) receptor antagonist

263 pyrazolo[1,5-a]-1,3,5-triazine corticotropin releasing factor receptor-1 (CRF(1)) receptor antagonist

264 is unaffected by alpha1-AR and corticotropin-releasing factor receptor-1 (CRFR(1)) antagonists, but i

265 tention were attenuated by the corticotropin-releasing factor receptor-1 antagonist antalarmin but no

266 application of urocortin I (a corticotrophin-releasing factor receptor-2 agonist) to the ventromedial

267 of the analogous domain of the corticotropin-releasing factor receptor.

268 Corticotropin-Releasing Factor Receptors (CRFRs) are class B1 G-protei

269 Corticotropin-releasing factor receptors (CRFRs), class B G protein-co

270 Codon selection, releasing factor recognition sequence and specific intro

271 Urocortin 3 (Ucn 3) is a corticotrophin-releasing factor related neuropeptide highly expressed i

272 he peptide antagonist, cyclic corticotrophin-releasing factor residues 30-41 (cCRF(30-41)), was calcu

273 ion-like protein (RepA-WH1) into the E. coli releasing factor RF1 promotes its aggregation and enable

274 Alterations in central corticotropin-releasing factor signaling pathways have been implicated

275 n-gamma (IFN-gamma) and induce cytolysis via releasing factors such as perforin, which permeabilizes

276 s), (4) the (gastrointestinal) corticotropin-releasing factor system, and (5) the intestinal response

277 In addition, corticotropin-releasing factor systems were shown to facilitate memory

278 s probed using a dexamethasone/corticotropin-releasing factor test.

279 These results reveal PAR polymer as an AIF-releasing factor that plays important roles in PARP-1-de

280 s circadian rhythms of locomotor behavior by releasing factors that act on receptor sites near the th

281 uscle laceration sites on a delivery vehicle releasing factors that induce cell activation and migrat

282 role in maintaining vascular homeostasis by releasing factors that regulate local blood flow, system

283 counteracting the functions of corticotropin-releasing factor, the primary stress-mediating neuropept

284 lin, nesfatin-1, somatostatin, corticotropin-releasing factor, thyrotropin-releasing hormone and calc

285 buting ions, removing neurotransmitters, and releasing factors to influence blood flow and neuronal a

286 ation between histamine release to histamine releasing factor/translationally controlled tumor protei

287 hesis was investigated for the corticotropin-releasing factor type 1 (CRF(1)) receptor using a novel

288 Corticotropin releasing factor type 1 (CRF1) is a key component in the

289 Activation of corticotropin-releasing factor type 1 (CRF1) receptors in the CeA play

290 ve effect is mediated via the corticotrophin-releasing factor type 1 receptor (CRF1R, also known as C

291 peated social stress decreased corticotropin-releasing factor type 1 receptor and increased mu-opioid

292 We found that corticotropin-releasing factor type 1 receptor within the paraventricu

293 LTCC-based mechanism; instead, corticotropin-releasing factor type 1 receptors (CRF1s) mediate alcoho

294 LTCC-based mechanism; instead, corticotropin-releasing factor type 1 receptors (CRF1s) mediate alcoho

295 o central anorectic effects of corticotropin-releasing factor type 2 (CRF(2)) receptor stimulation.

296 The corticotropin-releasing factor type 2 receptor (CRFR2) is suggested to

297 hat the mechanism involved the corticotropin-releasing factor type 2 receptor, cAMP elevation, and ac

298 , which required activation of corticotropin-releasing factor type-1 (CRF-R1) receptors.

299 ombined administration of those hypothalamic releasing factors, which have been identified as suppres

300 plantation of blank scaffolds, and scaffolds releasing factors without cells.